Zenas BioPharma Inc. (ZBIO)
| Bid | 10.01 |
| Market Cap | 483.1M |
| Revenue (ttm) | 5M |
| Net Income (ttm) | -156.99M |
| EPS (ttm) | -11.89 |
| PE Ratio (ttm) | -0.97 |
| Forward PE | -2.24 |
| Analyst | Buy |
| Ask | 11.8 |
| Volume | 175,174 |
| Avg. Volume (20D) | 185,477 |
| Open | 10.43 |
| Previous Close | 11.58 |
| Day's Range | 11.20 - 11.72 |
| 52-Week Range | 5.83 - 26.25 |
| Beta | -3.62 |
About ZBIO
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclo...
Analyst Forecast
According to 7 analyst ratings, the average rating for ZBIO stock is "Buy." The 12-month stock price forecast is $32.5, which is an increase of 181.14% from the latest price.
Stock Forecasts
22 hours ago · accessnewswire.com
June 16, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ZBIONEW YORK, NY / ACCESS Newswire / April 30, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securitie...
